Xilio Therapeutics Inc’s recently made public that its 10% Owner GILEAD SCIENCES, INC. acquired Company’s shares for reported $0.37 million on Apr 02 ’24. In the deal valued at $0.76 per share,485,250 shares were bought. As a result of this transaction, GILEAD SCIENCES, INC. now holds 7,345,473 shares worth roughly $7.71 million.
Then, Atlas Venture Fund XI, L.P. sold 733 shares, generating $469 in total proceeds. Upon selling the shares at $0.64, the 10% Owner now owns 2,019,563 shares.
Before that, Atlas Venture Fund XI, L.P. sold 267 shares. Xilio Therapeutics Inc shares valued at $171 were divested by the 10% Owner at a price of $0.64 per share. As a result of the transaction, Atlas Venture Fund XI, L.P. now holds 734,546 shares, worth roughly $0.77 million.
Chardan Capital Markets initiated its Xilio Therapeutics Inc [XLO] rating to a Buy in a research note published on December 21, 2022; the price target was $7. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. Raymond James began covering XLO with “an Outperform” recommendation on November 16, 2021. Morgan Stanley started covering the stock on November 16, 2021. It rated XLO as “an Overweight”.
Price Performance Review of XLO
On Tuesday, Xilio Therapeutics Inc [NASDAQ:XLO] saw its stock fall -4.55% to $1.05. Over the last five days, the stock has lost -19.23%. Xilio Therapeutics Inc shares have risen nearly 90.91% since the year began. Nevertheless, the stocks have fallen -67.29% over the past one year. While a 52-week high of $3.40 was reached on 03/28/24, a 52-week low of $0.49 was recorded on 02/14/24. SMA at 50 days reached $0.8859, while 200 days put it at $1.5494. A total of 0.45 million shares were traded, compared to the trading of 0.26 million shares in the previous session.
Levels Of Support And Resistance For XLO Stock
The 24-hour chart illustrates a support level at 0.9900, which if violated will result in even more drops to 0.9300. On the upside, there is a resistance level at 1.1300. A further resistance level may holdings at 1.2100. The Relative Strength Index (RSI) on the 14-day chart is 48.10, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1414, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.59%. Stochastics %K at 8.47% indicates the stock is a buying.
The most recent change occurred on November 16, 2021 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
